According to the WHO, at least a billion people are currently living with vision impairment from a preventable or treatable source. Precedence Research reports that the global ophthalmic drug market size is estimated to double in 10 years, from $34.6 billion in 2021 to an estimated $68.93 billion by 2030.

The development of pharmacological interventions for many of these conditions has been accelerating, supported by new delivery methods and formulation approaches. For conditions that require surgery or corrective devices, eye drops are an important part of diagnosis, and pre- and post-surgery treatment plans.

In Issue 43 of The Altascientist, we explore key considerations for ophthalmic product manufacturing, including formulation, scalability, regulatory compliance, and quality control:

• Recent developments in ophthalmic medications 
• Unique barriers for drug delivery to the eye
• Common types of ocular formulations
• Formulation for effective ocular drug delivery
• Systemic exposure of topical ophthalmic preparations
• Ocular gene therapy
• Manufacturing ocular drugs for clinical trials and commercialization
• A case study